[go: up one dir, main page]

EA201000784A1 - Антагонисты пути hedgehog и их терапевтические применения - Google Patents

Антагонисты пути hedgehog и их терапевтические применения

Info

Publication number
EA201000784A1
EA201000784A1 EA201000784A EA201000784A EA201000784A1 EA 201000784 A1 EA201000784 A1 EA 201000784A1 EA 201000784 A EA201000784 A EA 201000784A EA 201000784 A EA201000784 A EA 201000784A EA 201000784 A1 EA201000784 A1 EA 201000784A1
Authority
EA
Eurasian Patent Office
Prior art keywords
therapeutic applications
hedgehog antagonists
hedgehog
antagonists
pharmaceutical composition
Prior art date
Application number
EA201000784A
Other languages
English (en)
Other versions
EA017918B1 (ru
Inventor
Рассел Джон Томас
Гал.ла Перикот Мор
Джакомо Минетто
Анетта Корнелия Баккер
Пьетро Ферруцци
Original Assignee
СИЕНА БИОТЕК С.п.А.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by СИЕНА БИОТЕК С.п.А. filed Critical СИЕНА БИОТЕК С.п.А.
Publication of EA201000784A1 publication Critical patent/EA201000784A1/ru
Publication of EA017918B1 publication Critical patent/EA017918B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/18—Benzimidazoles; Hydrogenated benzimidazoles with aryl radicals directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Гетероциклические соединения, модулирующие сигнальный путь hedgehog, их фармацевтическая композиция и их терапевтические применения.
EA201000784A 2007-12-13 2008-12-10 Антагонисты пути hedgehog и их терапевтические применения EA017918B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07024218 2007-12-13
PCT/EP2008/010470 WO2009074300A2 (en) 2007-12-13 2008-12-10 Hedgehog pathway antagonists and therapeutic applications thereof

Publications (2)

Publication Number Publication Date
EA201000784A1 true EA201000784A1 (ru) 2010-12-30
EA017918B1 EA017918B1 (ru) 2013-04-30

Family

ID=39432963

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201000784A EA017918B1 (ru) 2007-12-13 2008-12-10 Антагонисты пути hedgehog и их терапевтические применения

Country Status (16)

Country Link
US (1) US8592463B2 (ru)
EP (1) EP2227456A2 (ru)
JP (1) JP5620821B2 (ru)
CN (1) CN101896472A (ru)
AR (1) AR069652A1 (ru)
AU (1) AU2008335880B2 (ru)
BR (1) BRPI0820856A2 (ru)
CA (1) CA2709203A1 (ru)
CO (1) CO6210735A2 (ru)
CR (1) CR11481A (ru)
EA (1) EA017918B1 (ru)
IL (1) IL206298A0 (ru)
NZ (1) NZ586121A (ru)
TW (1) TW200930370A (ru)
WO (1) WO2009074300A2 (ru)
ZA (1) ZA201004185B (ru)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI433674B (zh) 2006-12-28 2014-04-11 Infinity Discovery Inc 環杷明（ｃｙｃｌｏｐａｍｉｎｅ）類似物類
CN101918420A (zh) * 2007-12-27 2010-12-15 无限药品股份有限公司 癌症治疗方法
WO2009086451A1 (en) 2007-12-27 2009-07-09 Infinity Pharmaceuticals, Inc. Methods for stereoselective reduction
US20100297118A1 (en) * 2007-12-27 2010-11-25 Macdougall John Therapeutic Cancer Treatments
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
EP2424840B1 (en) * 2009-04-27 2014-08-06 Boehringer Ingelheim International GmbH Cxcr3 receptor antagonists
AU2010257802A1 (en) 2009-06-11 2012-01-12 Siena Biotech S.P.A. Hedgehog pathway antagonists and therapeutic applications thereof
AR077014A1 (es) * 2009-06-19 2011-07-27 Lilly Co Eli Compuesto derivado de ftalazina 1,4-disustituida, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para el tratamiento de cancer
EP2462115B1 (en) 2009-08-05 2016-01-06 Infinity Pharmaceuticals, Inc. Enzymatic transamination of cyclopamine analogs
US8952004B2 (en) 2010-01-07 2015-02-10 Boehringer Ingelheim International Gmbh CXCR3 receptor antagonists
US20110183948A1 (en) * 2010-01-15 2011-07-28 Infinity Pharmaceuticals, Inc. Treatment of fibrotic conditions using hedgehog inhibitors
WO2011146882A1 (en) 2010-05-21 2011-11-24 Intellikine, Inc. Chemical compounds, compositions and methods for kinase modulation
WO2012037217A1 (en) 2010-09-14 2012-03-22 Infinity Pharmaceuticals, Inc. Transfer hydrogenation of cyclopamine analogs
JP2013545749A (ja) 2010-11-10 2013-12-26 インフィニティー ファーマシューティカルズ， インコーポレイテッド 複素環化合物及びその使用
EP2468726B1 (en) 2010-12-06 2013-08-28 Siena Biotech S.p.A. Compound for the treatment of tumours and tumour metastases
PH12013501465A1 (en) 2011-01-10 2013-09-09 Infinity Pharmaceuticals Inc Processes for preparing isoquinolinones and solid forms of isoquinolinones
JP6027611B2 (ja) 2011-07-19 2016-11-16 インフィニティー ファーマシューティカルズ， インコーポレイテッド 複素環式化合物及びその使用
AU2012284088B2 (en) 2011-07-19 2015-10-08 Infinity Pharmaceuticals Inc. Heterocyclic compounds and uses thereof
FI20115785A0 (fi) * 2011-08-08 2011-08-08 Thermo Fisher Scientific Oy Menetelmä ja laite automaattiseen analyysiin
WO2013021101A1 (en) 2011-08-08 2013-02-14 Thermo Fisher Scientific Oy Method and apparatus for automated analysis
TW201311663A (zh) 2011-08-29 2013-03-16 Infinity Pharmaceuticals Inc 雜環化合物及其用途
WO2013049332A1 (en) 2011-09-29 2013-04-04 Infinity Pharmaceuticals, Inc. Inhibitors of monoacylglycerol lipase and methods of their use
CA2851082A1 (en) 2011-10-06 2013-04-11 Merck Sharp & Dohme Corp. 1,3-substituted azetidine pde10 inhibitors
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
NZ708563A (en) 2012-11-01 2019-02-22 Infinity Pharmaceuticals Inc Treatment of cancers using pi3 kinase isoform modulators
WO2014151386A1 (en) 2013-03-15 2014-09-25 Infinity Pharmaceuticals, Inc. Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
US9192609B2 (en) 2013-04-17 2015-11-24 Hedgepath Pharmaceuticals, Inc. Treatment and prognostic monitoring of proliferation disorders using hedgehog pathway inhibitors
CN103288803B (zh) * 2013-05-17 2017-10-31 郎恒元 苯并咪唑酰胺类化合物及其制备方法和应用
AU2014273946B2 (en) 2013-05-30 2020-03-12 Infinity Pharmaceuticals, Inc. Treatment of cancers using PI3 kinase isoform modulators
EP3003038B1 (en) * 2013-06-07 2019-08-14 The Scripps Research Institute 2h-1,2,3-triazole derivatives as inhibitors of fibrosis
PT3052485T (pt) 2013-10-04 2021-10-22 Infinity Pharmaceuticals Inc Compostos heterocíclicos e suas utilizações
WO2015061204A1 (en) 2013-10-21 2015-04-30 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
FR3017867A1 (fr) * 2014-02-21 2015-08-28 Inventiva Nouveaux composes de type phenylazetidine carboxylate ou carboxamide
AU2015231413B2 (en) 2014-03-19 2020-04-23 Infinity Pharmaceuticals, Inc. Heterocyclic compounds for use in the treatment of PI3K-gamma mediated disorders
WO2015160986A2 (en) 2014-04-16 2015-10-22 Infinity Pharmaceuticals, Inc. Combination therapies
WO2015168079A1 (en) 2014-04-29 2015-11-05 Infinity Pharmaceuticals, Inc. Pyrimidine or pyridine derivatives useful as pi3k inhibitors
WO2016054491A1 (en) 2014-10-03 2016-04-07 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
AU2015360583B2 (en) 2014-12-10 2020-01-23 The Scripps Research Institute Small molecule inhibitors of fibrosis
WO2016196928A1 (en) 2015-06-04 2016-12-08 PellePharm, Inc. Topical formulations for delivery of hedgehog inhibitor compounds and use thereof
WO2017139497A1 (en) 2016-02-11 2017-08-17 PellePharm, Inc. Hedgehog inhibitor for use in relief of and treatment of pruritus or itching
WO2017214269A1 (en) 2016-06-08 2017-12-14 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
AU2017281797A1 (en) 2016-06-24 2019-01-24 Infinity Pharmaceuticals, Inc. Combination therapies
CN109232533A (zh) * 2017-09-28 2019-01-18 北京越之康泰生物医药科技有限公司 氮杂环类衍生物、其制备方法及其医药用途
CN110494431B (zh) * 2017-09-30 2022-11-04 苏州浦合医药科技有限公司 氮杂环类衍生物、其制备方法及其医药用途
CN110016054B (zh) * 2019-03-15 2021-10-22 四川大学 含磷氮苯并杂环结构的离子单体、用其阻燃的共聚酯型离聚物及它们的制备方法和应用
CN114790177B (zh) * 2021-01-26 2024-03-26 首都医科大学附属北京天坛医院 新型Hedgehog信号通路抑制剂

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR200200972T2 (tr) * 1998-11-03 2002-07-22 Basf Aktiengesellschaft İkameli 2-fenilbenzimidazoller, üretimleri ve kullanımları
EP1435947B1 (en) * 2001-10-19 2007-08-15 Ortho-McNeil Pharmaceutical, Inc. 2-phenyl benzimidazoles and imidazo-¬4,5|-pyridines as cds1/chk2-inhibitors and adjuvants to chemotherapy or radiation therapy in the treatment of cancer
CN101597262A (zh) * 2002-03-05 2009-12-09 特兰斯泰克制药公司 抑制配体与高级糖化终产物受体相互作用的单和双环吡咯衍生物
AU2010257802A1 (en) * 2009-06-11 2012-01-12 Siena Biotech S.P.A. Hedgehog pathway antagonists and therapeutic applications thereof

Also Published As

Publication number Publication date
CA2709203A1 (en) 2009-06-18
CR11481A (es) 2010-10-15
US20100286114A1 (en) 2010-11-11
WO2009074300A3 (en) 2009-10-01
ZA201004185B (en) 2011-10-26
CO6210735A2 (es) 2010-10-20
BRPI0820856A2 (pt) 2019-05-14
EP2227456A2 (en) 2010-09-15
WO2009074300A2 (en) 2009-06-18
JP5620821B2 (ja) 2014-11-05
TW200930370A (en) 2009-07-16
JP2011506366A (ja) 2011-03-03
AR069652A1 (es) 2010-02-10
US8592463B2 (en) 2013-11-26
EA017918B1 (ru) 2013-04-30
WO2009074300A8 (en) 2009-11-19
IL206298A0 (en) 2010-12-30
CN101896472A (zh) 2010-11-24
NZ586121A (en) 2012-03-30
AU2008335880B2 (en) 2014-03-13
AU2008335880A1 (en) 2009-06-18

Similar Documents

Publication Publication Date Title
EA201000784A1 (ru) Антагонисты пути hedgehog и их терапевтические применения
EA200900781A1 (ru) 4-фенилпиран-3,5-дионы, 4-фенилтиопиран-3,5-дионы и циклогексантрионы, как новые гербициды
EA201000888A1 (ru) 4-фенилпиран-3,5-дионы, 4-фенилтиопиран-3,5-дионы и 2-фенилциклогексан-1,3,5-трионы в качестве гербицидов
CL2008002097A1 (es) Compuestos derivados de heterociclos condensados sustituidos, inhibidores de cinasa de fosfatidil-inositol-3; composicion farmaceutica; y uso en el tratamiento del cancer.
DK1928438T3 (da) Anvendelse af ibudilast til behandling af stofafhængighed
EA200802008A1 (ru) Фармацевтические композиции
DK1981889T3 (da) Cytotoksiske midler, der omfatter nye tomaymycin-derivater, og terapeutisk anvendelse deraf
EA201001329A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
EA201170227A1 (ru) Имидазолкарбоксамиды
BRPI0810646A2 (pt) " compostos farmacêuticos ".
EA201200550A1 (ru) Фармацевтические композиции, включающие bi-1356 и метформин
CL2007002167A1 (es) Compuestos derivados de indol, antagonistas iap; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de cancer.
CL2011003147A1 (es) Compuestos derivados de n-(1-4-(1h-pirazol-5-il)ftalazina-1-il) piperidina-4-il) benzamida; composicion farmaceutica que los contiene, utiles como antagonista de la trayectoria de hedgehog, en el tratamiento del cancer.
EA201001332A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
CL2011000846A1 (es) Compuestos heterociclicos sustituidos; composicion farmaceutica; y su uso para el tratamiento de la hepatitis c.
EA201000258A1 (ru) Новые гербициды
CR11057A (es) Nuevos compuestos heterociclicos nitrogenados, su preparacion y su utilizacion como medicamentos antibacterianos
PA8720801A1 (es) Nuevas combinaciones terapeuticas para el tratamiento de la depresion
DK2207773T3 (da) Heterocyklisk forbindelse og farmaceutisk sammensætning deraf.
MX2010006206A (es) Derivados de oxindol substituidos por 5-halogeno y el uso de los mismos para el tratamiento de enfermedades dependientes de la vasopresina.
EA201001330A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
ATE544759T1 (de) 5-pyridinon-substituierte indazole und pharmazeutische zusammensetzungen davon
CY1114023T1 (el) Διυποκατεστημενης φθαλαζινης ανταγωνιστες σηματοδοτικης οδου hedgehog
EA201070059A1 (ru) Композиции, содержащие ингибиторы триптофангидроксилазы
BRPI0816992A2 (pt) Derivado heterocíclico tricícloco, e, composição farmacêutica

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): RU